Effects of an agonist interleukin-2/Fc fusion protein, a mutant antagonist interleukin-15/Fc fusion protein, and sirolimus on cardiac allograft survival in non-human primates
Timothy Millington, Maria Koulmanda, Choo Ng, Svjetlan Boskovic, Ognjenka M Nadazdin, Gilles Benichou, Xin Xiao Zheng, Terry B Strom, Joren C Madsen
JOURNAL OF HEART AND LUNG TRANSPLANTATION | ELSEVIER SCIENCE INC | Published : 2012
BACKGROUND: To tilt the immunologic balance toward tolerance and away from rejection, non-human primate recipients of cardiac allografts were treated with interleukin (IL)-2/Fc, mutant (m) antagonist type mIL-15/Fc, and sirolimus. METHODS: Heterotopic heart transplants were performed on 8 fully mismatched cynomolgus macaques. An untreated control recipient rejected its graft by post-operative Day 6. The remaining 7 animals received oral or intramuscular immunosuppression with sirolimus. A recipient treated with sirolimus alone rejected at the end of 28 days of immunosuppression. The remaining 6 monkeys also received IL-2/Fc and mIL-15/Fc intramuscularly until 28 days after transplant. One an..View full abstract
Awarded by National Institute of Allergy and Infectious Disease of the National Institutes of Health
Awarded by Medical Research Council
Awarded by NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
This work was partly supported by the National Institute of Allergy and Infectious Disease (U19AI066705) of the National Institutes of Health. T.M. is the recipient of an International Society for Heart and Lung Transplantation (ISHLT) Research Fellowship.